Response to the letter to the editor on “Clinical efficacy and safety of molnupiravir for nonhospitalized and hospitalized patients with COVID‐19: A systematic review and meta‐analysis of randomized control trials”-Reference-Cited by-同舟云学术

Response to the letter to the editor on “Clinical efficacy and safety of molnupiravir for nonhospitalized and hospitalized patients with COVID‐19: A systematic review and meta‐analysis of randomized control trials”

Published:2023-07 Issue:7 Volume:95 Page:
ISSN:0146-6615
Container-title:Journal of Medical Virology
language:en
Short-container-title:Journal of Medical Virology

Author:

Huang Po‐Yu¹^ORCID,Liu Ting‐Hui²,Wu Jheng‐Yan³^ORCID,Tsai Ya‐Wen⁴^ORCID,Lai Chih‐Cheng⁵⁶^ORCID

Affiliation:

1. Department of Internal Medicine Chi Mei Medical Center Tainan City Taiwan

2. Department of Psychiatry Chi Mei Medical Center Tainan Taiwan

3. Department of Nutrition Chi Mei Medical Center Tainan Taiwan

4. Center of Integrative Medicine Chi Mei Medical Center Tainan Taiwan

5. Division of Hospital Medicine, Department of Internal Medicine Chi Mei Medical Center Tainan Taiwan

6. School of Medicine, College of Medicine National Sun Yat‐sen University Kaohsiung Taiwan

Publisher

Wiley

Subject

Infectious Diseases,Virology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.28918

Reference7 articles.

1. Clinical efficacy and safety of molnupiravir for nonhospitalized and hospitalized patients with COVID‐19: A systematic review and meta‐analysis of randomized control trials

2. Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults

3. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

4. Efficacy and safety of molnupiravir for the treatment of non‐hospitalized adults with mild Covid‐19: a randomized, open‐label, parallel group phase trial;Tippabhotla SK;Lancet,2022

5. Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19